Abstract
MicroRNAs have been predicted to regulate the stability and translation of many target mRNAs that are involved in modulating disease outcome. Thus, valuable strategies to enhance or to diminish the function of microRNAs are needed to manipulate microRNA-mediated target gene expression. Recently, it has become apparent that one class of antisense oligonucleotides, locked nucleic acids, can be used to sequester microRNAs in the liver of a variety of animals including humans, opening the possibility of applying locked nucleic acid-mediated gene therapy. This review summarizes the success of sequestration of liver-specific microRNA miR-122 by antisense locked nucleic acids and their use in combating hepatitis C virus in clinical trials.
Keywords: Clinical trials, gene targeting, hepatitis C virus, locked nucleic acids, microRNA-mRNA interactions, viral gene expression.
Current Gene Therapy
Title:Combating Hepatitis C Virus by Targeting MicroRNA-122 Using Locked Nucleic Acids
Volume: 12 Issue: 4
Author(s): Erica S. Machlin, Peter Sarnow and Selena M. Sagan
Affiliation:
Keywords: Clinical trials, gene targeting, hepatitis C virus, locked nucleic acids, microRNA-mRNA interactions, viral gene expression.
Abstract: MicroRNAs have been predicted to regulate the stability and translation of many target mRNAs that are involved in modulating disease outcome. Thus, valuable strategies to enhance or to diminish the function of microRNAs are needed to manipulate microRNA-mediated target gene expression. Recently, it has become apparent that one class of antisense oligonucleotides, locked nucleic acids, can be used to sequester microRNAs in the liver of a variety of animals including humans, opening the possibility of applying locked nucleic acid-mediated gene therapy. This review summarizes the success of sequestration of liver-specific microRNA miR-122 by antisense locked nucleic acids and their use in combating hepatitis C virus in clinical trials.
Export Options
About this article
Cite this article as:
Machlin S. Erica, Sarnow Peter and Sagan M. Selena, Combating Hepatitis C Virus by Targeting MicroRNA-122 Using Locked Nucleic Acids, Current Gene Therapy 2012; 12 (4) . https://dx.doi.org/10.2174/156652312802083558
DOI https://dx.doi.org/10.2174/156652312802083558 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cytomegalovirus Prophylaxis in Solid Organ Transplantation
Current Medicinal Chemistry Do Not Say Ever Never More: The Ins and Outs of Antiangiogenic Therapies
Current Pharmaceutical Design Management and Outcome of Heparin-Induced Thrombocytopenia in Pregnancy: A Systematic Review
Cardiovascular & Hematological Agents in Medicinal Chemistry Editorial (Thematic Issue: New Technological and Clinical Trends in Blood Pressure Theranostics: Is it Time to Consider a Spatio-Temporal Approach?)
Current Pharmaceutical Design Editorial (Current and Emerging Pharmacological Therapies of Ischaemic Stroke)
CNS & Neurological Disorders - Drug Targets The Association Between Diabetes and Cognitive Function in Later Life
Current Aging Science Lipids, Statins and Heart Failure: An Update
Current Pharmaceutical Design Sex-Gender Differences in Diabetes Vascular Complications and Treatment
Endocrine, Metabolic & Immune Disorders - Drug Targets Hypertensive Left Ventricular Hypertrophy Regression: Does It Matter?
Current Hypertension Reviews Activating Mutations of ESR1, BRCA1 and CYP19 Aromatase Genes Confer Tumor Response in Breast Cancers Treated with Antiestrogens
Recent Patents on Anti-Cancer Drug Discovery Anti-Inflammatory and Pro-Resolving Effects of N-3 PUFA in Cancers: Structures and Mechanisms
Current Topics in Medicinal Chemistry Formulation and In Vitro Evaluation of Solid Lipid Microparticles of Candesartan Cilexetil Floating Tablets
Drug Delivery Letters Advancement in Obesity Management: Leptin and Adiponectin Patents
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery The Effects of Psychotropic Drugs on the Regulation of Glucose Metabolism
Current Diabetes Reviews Cardiovascular Risk Factors in Chronic Inflammatory Rheumatic Diseases: Modern Assessment and Diagnosis
Current Vascular Pharmacology Clinical Evidence of Herb-Drug Interactions: A Systematic Review by the Natural Standard Research Collaboration
Current Drug Metabolism Inflammation, Sleep, Obesity and Cardiovascular Disease.
Current Vascular Pharmacology Therapeutic Interventions for Advanced Glycation-End Products and its Receptor- Mediated Cardiovascular Disease
Current Pharmaceutical Design Glycogen Phosphoprylase (EC 2.4.1.1) Activity During Cardiopulmonary Bypass in Patients Undergoing Cardiac Surgery
Vascular Disease Prevention (Discontinued) An Insight into Molecular Mechanisms and Novel Therapeutic Approaches in Epileptogenesis
CNS & Neurological Disorders - Drug Targets